Fosamax Once-Weekly Generics Could Launch In 2008 Following Court Ruling
This article was originally published in The Pink Sheet Daily
Executive Summary
Appeals court overturns a Wilmington, Del. federal judge’s ruling and finds that a Merck patent covering once-weekly alendronate dosing is invalid. The patent was originally slated to expire in 2019, and the court decision means generic versions could enter the market 11 years earlier than expected.
You may also be interested in...
Merck's Fosamax Plus D To Be Priced On Par With Predecessor
Merck's Fosamax Plus D adds weekly dose of vitamin D to the once-weekly osteoporosis agent. Plus D will reach the market around the same time as Roche/GlaxoSmithKline's once-monthly Boniva.
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.